U.S. Markets close in 5 hrs 20 mins
  • S&P 500

    3,688.66
    +21.94 (+0.60%)
     
  • Dow 30

    30,114.73
    +145.21 (+0.48%)
     
  • Nasdaq

    12,427.42
    +50.24 (+0.41%)
     
  • Russell 2000

    1,868.59
    +19.89 (+1.08%)
     
  • Crude Oil

    46.13
    +0.49 (+1.07%)
     
  • Gold

    1,837.50
    -3.60 (-0.20%)
     
  • Silver

    24.17
    +0.04 (+0.16%)
     
  • EUR/USD

    1.2152
    +0.0003 (+0.0243%)
     
  • 10-Yr Bond

    0.9730
    +0.0530 (+5.76%)
     
  • Vix

    20.81
    -0.47 (-2.21%)
     
  • GBP/USD

    1.3480
    +0.0027 (+0.2022%)
     
  • USD/JPY

    104.0860
    +0.2260 (+0.2176%)
     
  • BTC-USD

    18,989.09
    -268.49 (-1.39%)
     
  • CMC Crypto 200

    372.38
    -6.86 (-1.81%)
     
  • FTSE 100

    6,555.08
    +64.81 (+1.00%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

SeaSpine Holdings: Q3 Earnings Insights

Benzinga Insights
·1 min read

Shares of SeaSpine Holdings (NASDAQ:SPNE) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 52.94% year over year to ($0.24), which beat the estimate of ($0.31).

Revenue of $43,209,000 higher by 8.33% from the same period last year, which beat the estimate of $41,960,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Q4 revenue expected to be between $47,000,000 and $48,000,000.

How To Listen To The Conference Call

Date: Nov 09, 2020

View more earnings on SPNE

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/vdzfdwdf

Price Action

52-week high: $16.91

52-week low: $4.02

Price action over last quarter: Up 8.03%

Company Description

SeaSpine Holdings Corp is a medical technology company. It focuses on design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It has orthobiologics and spinal infusion hardware product categories. Its products are anterior and posterior fixation, access systems, bone graft substitutes, and collagen ceramic metrix. The company mainly operates in North America, Europe, Asia-Pacific and Latin America. It generates revenue by consigning or loaning its products to hospitals and independent sales agents.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.